Wedbush analyst Liana Moussatos maintained a Buy rating on Eiger Biopharmaceuticals (EIGR) today and set a price target of $43. The company’s shares opened today at $13.18.
According to TipRanks.com, Moussatos is ranked 0 out of 5 stars with an average return of -10.9% and a 35.0% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Aquestive Therapeutics Inc, and Catabasis Pharmaceuticals.
Eiger Biopharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $47.
See today’s analyst top recommended stocks >>
Based on Eiger Biopharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $17.14 million. In comparison, last year the company had a GAAP net loss of $10.89 million.
Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EIGR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eiger BioPharmaceuticals, Inc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for orphan diseases. It focuses on product candidates for the treatment of orphan diseases such as Sarasar, Pegylated Interferon Lambda, Exendin 9-39, and Ubenimex.
